Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Employees
138,200
Headquarters
Website
JNJ Metrics
BasicAdvanced
$582B
21.90
$11.03
0.35
$5.20
2.15%
Price and volume
Market cap
$582B
Beta
0.35
52-week high
$251.71
52-week low
$141.50
Average daily volume
8.8M
Dividend rate
$5.20
Financial strength
Current ratio
1.028
Quick ratio
0.689
Long term debt to equity
50.081
Total debt to equity
57.766
Dividend payout ratio (TTM)
46.19%
Interest coverage (TTM)
27.12%
Profitability
EBITDA (TTM)
33,059.665
Gross margin (TTM)
68.07%
Net profit margin (TTM)
28.46%
Operating margin (TTM)
27.96%
Effective tax rate (TTM)
17.73%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
8.68%
Return on equity (TTM)
35.56%
Valuation
Price to earnings (TTM)
21.897
Price to revenue (TTM)
6.173
Price to book
7.13
Price to tangible book (TTM)
-32.99
Price to free cash flow (TTM)
30.106
Free cash flow yield (TTM)
3.32%
Free cash flow per share (TTM)
8.022
Dividend yield (TTM)
2.15%
Forward dividend yield
2.15%
Growth
Revenue change (TTM)
6.05%
Earnings per share change (TTM)
90.50%
3-year revenue growth (CAGR)
5.60%
10-year revenue growth (CAGR)
3.00%
3-year earnings per share growth (CAGR)
17.90%
10-year earnings per share growth (CAGR)
7.25%
3-year dividend per share growth (CAGR)
4.92%
10-year dividend per share growth (CAGR)
5.71%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Business Wire·4 days ago
Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action
Reuters·2 weeks ago
Johnson & Johnson launches website for direct-to-consumer sales
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $582B as of March 16, 2026.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 21.9 as of March 16, 2026.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of March 16, 2026, the dividend rate is $5.2 and the yield is 2.15%. Johnson & Johnson has a payout ratio of 46.19% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment date is unconfirmed.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.